Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

ruxolitinib 23Cyclophosphamide 13Whole-Body Irradiation 10Tacrolimus 9Mycophenolic Acid 9fludarabine phosphate 8fludarabine 8Stem Cell Transplantation 8Specimen Handling 7Peripheral Blood Stem Cell Transplantation 7Busulfan 5Azacitidine 5navitoclax 4Sirolimus 4Melphalan 4Biopsy 4luspatercept 3fedratinib 3Methotrexate 3Cyclosporine 3venetoclax 2selinexor 2parsaclisib 2letermovir 2itacitinib 2bomedemstat 2Injections 2INCB057643 2INCB039110 2Hematopoietic Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × umbralisib × 1 year × Clear all
NCT02493530 2026-05-19

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
60 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡